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Abstract 
GH plays a major role in the regulation of lipid metabolism and alterations in GH axis elicit major changes in fat 
distribution and mobilization. For example, in patients with GH deficiency (GHD) or in mice lacking the GH 
receptor, the percentage of fat is increased. In addition to the direct actions of GH on lipid metabolism, current 
evidence indicates that ghrelin, a stomach-derived peptide hormone with potent GH secretagogue action, increases 
lipogenesis in white adipose tissue (WAT) through a hypothalamic-mediated mechanism. Still, the mechanism by 
which GH tone modulates ghrelin actions on WAT remains unclear. Here we investigated the effect of central ghrelin 
administration on lipid metabolism in lipogenic tissues (liver and WAT) in the absence of GH, by using a model for 
the study of GHD, namely the spontaneous dwarf rat, which shows increased body fat. Our data demonstrate that 
central chronic ghrelin administration regulates adipose lipid metabolism, mainly in a GH-independent fashion, as a 
result of increased mRNA, protein expression, and activity levels of fatty acid metabolism enzymes. On the contrary, 
central ghrelin regulates hepatic lipogenesis de novo in a GH-independent fashion but lipid mobilization in a GH-
dependent fashion because carnitine palmitoyltransferase 1 was decreased only in wild-type Lewis rats. These 
findings suggest the existence of a new central nervous system-based neuroendocrine circuit, regulating metabolic 
homeostasis of adipose tissue. Understanding the molecular mechanism underlying the interplay between GH and 
ghrelin and their effects on lipid metabolism will provide new strategies for the design and development of suitable 
drugs for the treatment of GHD, obesity, and its comorbidities. 
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The metabolic processes controlled by GH are multiple and complex, and its effects on body 
composition and intermediary metabolism have been known for many years. GH plays a major role in the 
regulation of lipid metabolism, and alterations in GH axis elicit major changes in fat distribution and 
mobilization. This is the reason that patients with GH deficiency (GHD) display increased percentage of 
fat, which has been recognized as a clinical hallmark that rapidly disappears during the early months of 
treatment with GH. The adverse lipid profile in subjects with GHD and the mortality associated with this 
altered lipid profile is the risk factor that has probably attracted most attention in recent years. GHD is 
associated with conditions related to hyperlipidemia, increased body weight, abnormal body composition, 
and fat accumulation, and GH replacement in these patients has demonstrated beneficial on 
cardiovascular risk factors (1–7). 
 
Ghrelin is a 28-residue peptide hormone from the stomach and acts as the endogenous ligand to GH 
secretagogue receptor (GHS-R) (8–11), which is expressed in the brain and peripheral tissues (12). In 
addition to its role as a stimulator of GH release, ghrelin promotes feeding in humans and rodents, which 
results in increased body weight and adiposity (11, 13–16). The effects of ghrelin on feeding behavior are 
believed to be mediated at the level of the hypothalamus by a mechanism involving hypothalamic AMP-
activated protein kinase (AMPK), lipid metabolism (Fig. 1A), uncoupling protein-2, and neuropeptide 
gene expression (17–19). In addition, recent evidence has demonstrated that central administration of 
ghrelin directly increases adiposity by stimulation of the lipogenic program in the white adipose tissue 
(WAT), via the sympathetic nervous system, in a food intake-independent fashion (16, 20). More 
specifically central ghrelin administration induced the mRNA expression of various fat storage-promoting 
enzymes in WAT, such as lipoprotein lipase, acetyl-CoA carboxylase (ACC)-α, fatty acid synthase 
(FAS), and stearoyl-CoA desaturase (SCD)-1, whereas that of the rate-limiting step in fat oxidation, 
carnitine palmitoyltransferase 1 (CPT1), was decreased (16). This evidence indicates that central ghrelin 
action is of physiological relevance in the control of adipocyte metabolism and suggests that ghrelin could 
trigger meal preparation processes in the central nervous system (CNS), preparing metabolic pathways 
that would lead to a more efficient storage of calories. 
 
 
 
Fig. 1 Squematic representation of the synthesis and oxidation of fatty acids, ACL: ATP-
citrate lyase (A), hepatic mRNA (B), protein (C and D), and activity levels (E) of lipid 
metabolism-related enzymes in fed and fasted rats. Values are means ± sem of eight 
animals per group. *, **, ***, P < 0.05, 0.01, and 0.001, respectively, vs. fed. #, ##, ###, 
P < 0.05, 0.01, and 0.001, respectively, vs. wild-type Lewis. ACL, ATP-citrate lyase. 
 
 
  
Despite this evidence that links GH axis and ghrelin to lipid metabolism, the relevance of the GH tone 
on the lipogenic effect of ghrelin remains unclear. Although several studies in GH-deficient rats have 
demonstrated that weight gain and adiposity caused by ghrelin are independent of its ability to modulate 
GH secretion (11, 13, 15, 21), GH receptor deficiency blunts the stimulatory effects of ghrelin on feeding 
in mice (22). The aim of this study was to investigate the effect of central ghrelin administration on lipid 
metabolism in major lipogenic tissues, such as liver and adipose tissue, in absence of GH. We used the 
spontaneous dwarf rat, which is a classical model for the study of GHD (23, 24). Our data show that 
central ghrelin regulates adipocyte lipid metabolism in a GH-independent fashion, whereas central ghrelin 
regulates hepatic lipid mobilization in a GH-dependent fashion. These findings suggest the existence of a 
new CNS-based neuroendocrine circuit regulating metabolic homeostasis of adipose tissue. 
Materials and Methods 
Animals 
We used two male rat models, wild-type (controls) and GH-deficient (spontaneous dwarf rat) Lewis 
rats (2–3 months old; body weight 365 g ± 4 and 222 g ± 5 g, respectively; Harlan, Bicester, UK). Rats 
were housed in a temperature-controlled room, with a 12-h light, 12-h dark cycle (lights from 0800 to 
2000 h). All experiments and procedures involved in this study were reviewed and approved by the Ethics 
Committee of the University of Santiago de Compostela, in accordance with European Union Normative 
for the use of experimental animals. 
Fasting experiment 
To study hepatic and fat metabolism in a natural situation with high levels of ghrelin and 
absence/presence of GH, wild-type and GH-deficient rats were fasted during 48 h. 
Infusion of ghrelin into lateral ventricle in wild-type and GH-deficient Lewis rats 
To assess chronic effects of intracerebroventricular (ICV) ghrelin on epididymal WAT and hepatic 
metabolism in presence and absence of GH, normal and GH-deficient rats were infused with saline as 
vehicle (controls) or acyl-ghrelin, 20 μg/d for 8 d. 
Implantation of intracerebroventricular (ICV) cannulae 
Chronic ICV cannulae were implanted under ketamine/xylazine anesthesia as previously described 
(17, 25). The correct location of the cannulae in the lateral ventricle was confirmed by methylene blue 
staining. Animals were individually caged and allowed to recover for 1 wk before the experiment. During 
the postoperative recovery period, the rats were handled regularly under nonstressful conditions. 
Chronic ghrelin treatment 
Brain infusion cannulae were stereotaxically placed into the lateral ventricle as described above. A 
catheter tube was connected from the brain infusion cannulae to an osmotic minipump flow moderator 
(model 2001D or 2ML2; Alzet Corp., Palo Alto, CA). An sc pocket on the dorsal surface of the animal 
was created using blunt dissection, and the osmotic minipump was inserted. The incision was closed with 
sutures, and the rats were kept warm until fully recovered. The rats were then infused with either vehicle 
alone (saline) or vehicle containing acyl-ghrelin (Bachem, Bubendorf, Switzerland; catalog no. H-4864), 
the pumps released the solutions at a rate of 1 μl/h and 20 μg ghrelin/d. Animals were treated during 8 d. 
Acute ghrelin treatment 
To study the influence of the acylation state on food intake, wild-type rats were treated with a single 
ICV injection of 5 μl of either saline or 5 μg acyl-ghrelin and/or 5 μg desacyl-ghrelin (Bachem; catalog 
no. H-5946). Food intake was measured during 6 h. 
Tissue dissection 
Rats were killed by cervical dislocation and trunk blood was extracted. The following tissues were 
dissected and weighed: liver, brown adipose tissue, and visceral, retroperitoneal, omental, and epididymal 
WAT and somatic index were calculated. Samples were stored at −80 C until further processing and 
parameters measurement. 
Plasma measurements 
Plasma total ghrelin and insulin levels were measured by RIA as described previously (17, 25) using 
reagents provided in commercial kits (catalog no. GHRT-89K and RI-13K, respectively; Linco Research 
Inc., St. Charles, MO). Plasma glucose and triglyceride levels were assessed using a commercial kit based 
on a colorimetric method (Glucose and Triglyceride Spinreact, Spain). 
Real-time quantitative PCR 
Expression of mRNA levels of ACCα, CPT1M (muscle type isoform), and CPT1L (liver type 
isoform), FAS, SCD-1, and malonyl-CoA decarboxylase (MCD) in liver and epididymal WAT were 
studied by using real-time PCR (TaqMan; Applied Biosystems, Foster City, CA) by using specific 
primers and probes (supplemental Table S1). All reactions were carried out using the following cycling 
parameters: 50 C for 2 min, 95 C for 10 min followed by 40 cycles of 95 C for 15 sec, 60 C for 1 min (17, 
25). For data analysis, the input value of the target gene was standardized to the 18S value for each 
sample. Data were expressed in comparison with the average value for the vehicle treated rats (control 
group). We used eight rats per group. 
Western blotting 
Total protein lysates from liver (20 μg) and epididymal WAT (15 μg) were subjected to SDS-PAGE, 
electrotransferred on a polyvinylidene difluoride membrane and probed with the indicated antibodies: 
ACC, phospho-ACC-Ser79 (pACC), AMPKα1 and AMPKα2 (Upstate, Lake Placid, NY); phospho-
AMPKα-Thr172 (pAMPKα) (Cell Signaling, Danvers, MA); β-actin (Abcam, Cambridge, UK); CPT1M, 
FAS, and CPT1L (Santa Cruz Biotechnology, Santa Cruz, CA). For protein detection we used horseradish 
peroxidase-conjugated secondary antibodies and chemiluminescence (Amersham Biosciences, Little 
Chalfont, UK). We used eight rats per group and the protein levels were normalized to β-actin for each 
sample. 
Enzyme assays 
Tissue samples were homogenized in 10 volumes (liver) or four volumes (adipose tissue) ice-cold 
buffer: 20 mm Tris-HCl (pH 7.4), 250 mm sucrose, 1 mm EDTA, 1 mm dithiothreitol, 100 mm NaF, and 
protease inhibitor cocktail (Roche, Stockholm, Sweden). Enzyme activities of FAS, MCD, CPT1, 
glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH) were 
determined by spectrophotometry using a microplate reader (Tecan, Sunrise, Switzerland). The reactions 
were started by the addition of homogenates (30 μl) and substrates (20 μl, omitted in controls) to the 
reaction mixture (final volume 0.25 ml) and allowing the reactions to proceed at 37 C for preestablished 
times (5–15 min). FAS (26), G6PDH, 6PGDH (27, 28), CPT1 (17, 25, 29, 30), and MCD (31) activities 
were measured using methods previously described. ACC activity was assayed using an isotopic method 
(32) by 
14
co2 fixation to acid-stable products. 
  
Malonyl-CoA assay 
Malonyl-CoA levels were assessed radioenzymatically by a modification of the method of McGarry et 
al. (33) as described previously (17, 34). 
Statistical analysis 
Date were expresses as percentage of wild-type fed rats or wild type infused with saline (control 
groups). Data were expressed as mean ± sem. Statistic significance was determined by two-way ANOVA 
and post hoc Tukey test. P < 0.05 was considered significant. 
Results 
Effects of fasting on plasma levels 
Plasma parameters are shown in supplemental Table S2. In 48-h-fasted wild-type Lewis rats, plasma 
ghrelin levels increased by 80% when compared with the fed group, whereas in the dwarf group, the 
levels were increased by just 40%. In the fed normal state, plasma insulin levels in dwarf rats were lower 
than in normal rats; GH-deficient rats exhibited normoglycemia compared with wild-type Lewis. After 48 
h of fasting, plasma insulin, glucose, and triglyceride levels diminished in both animal models. 
Effects of fasting on liver lipid metabolism 
Gene expression, protein, and activity levels of key enzymes involved in the regulation of lipid 
metabolism in liver of fed and food-deprived Lewis and dwarf rats are shown in Fig. 1, B–E. As 
expected, fasting markedly diminished mRNA levels of the fat storage-promoting enzymes, such as 
ACCα, FAS, and SCD-1 and enhanced mRNA levels of those involved in fatty acid degradation, such as 
CPT1L and MCD, which were higher in fed dwarf rats compared with fed normal Lewis rats (Fig. 1B). 
After 48 h of fasting, the protein levels of pAMPKα, pACCα, ACCα, CPT1L, and FAS significantly 
diminished in normal and GH-deficient rats; however, protein levels of AMPKα1 and AMPKα2 
significantly diminished only in the dwarf group. Protein levels of ACCα and FAS were higher in fed 
dwarf rats, whereas protein levels of CPT1L were lower in this model compared with their controls (Fig. 
1, C and D). In normal and GH-deficient rats, FAS, G6PDH, and 6PGDH activities decreased after 
fasting, whereas the activities of enzymes involved in fatty acid degradation were enhanced. Anew the 
activity of enzymes related with lipogenesis, such as FAS and 6PGDH, was increased in fed dwarf rats 
compared with their controls (Fig. 1E). 
Effects of fasting on WAT lipid metabolism 
We studied the fasting-induced effect on key enzymes of lipid metabolism in wild-type and GH-
deficient Lewis rats. The results are shown in Fig. 2, A–D. As expected, food deprivation clearly 
diminished mRNA levels of ACCα, FAS, CPT1M, SCD-1, and increased mRNA levels of MCD (Fig. 
2A). After fasting, protein levels of pAMPKα and AMPKα1 significantly diminished in GH-deficient rats 
but not normal rats, whereas protein levels of ACCα, pACCα, FAS, and CPT1M significantly diminished 
in both models of rats, although the decrease was more striking in dwarf rats. In all cases the protein 
levels of these enzymes were higher in fed dwarf rats compared with their controls (Fig. 2, B and C). 
FAS, G6PDH, 6PGDH, CPT1, and MCD activities were lower after 48 h of food deprivation in both 
animal models, although in normal rats only FAS and G6PDH activities decreased significantly. The 
activity of FAS, CPT1, and MCD was higher in fed dwarf rats compared with their controls (Fig. 2D). 
 
 
 
Fig. 2 Epididymal WAT mRNA (A), protein (B and C), and activity levels (D) 
of lipid metabolism-related enzymes in fed and fasted Lewis rats. Values are 
expressed as mean ± sem. *, **, ***, P < 0.05, 0.01, and 0.001, respectively, 
vs. fed. #, ##, ###, P < 0.05, 0.01, and 0.001, respectively, vs. wild-type Lewis. 
Effects of central ghrelin treatment on food intake and body weight gain in wild-type Lewis rats 
To throw some light on the mechanism involved in fasting-induced changes in lipid metabolism in 
normal and GH-deficient rats, we assessed the central effects of ghrelin in both experimental models. As 
expected chronic ICV ghrelin treatment increased food intake (Fig. 3, A and B), body weight gain (Fig. 
3C), and food efficiency (Fig. 3D) as well as percent omental and visceral WAT (Fig. 3E) during the 8-d 
experimental period in wild-type Lewis rats in comparison with their saline-treated controls. 
 
 
 
 
Fig. 3 Effect of an 8-d ICV ghrelin treatment on cumulative food intake (A), cumulative daily food 
intake (B), body weight gain (C), food efficiency (D), somatic index (E), and sum of retroperitoneal, 
omental, epididymal, and visceral adipose tissue (F) in wild-type Lewis rats. Values are expressed as 
mean ± sem. *, **, ***, P < 0.05, 0.01, and 0.001, respectively, vs. saline. Somatic index was 
calculated as the ratio between tissue weight and body weight and was expressed as a percentage. 
Food efficiency was calculated as the ratio between body weight gain over the 8-d experimental 
period and cumulative food intake and was expressed as a percentage.
Effects of central ghrelin treatment on plasma parameters in wild-type Lewis rats 
As previously reported (16), ICV ghrelin administration elicited an increase in plasma ghrelin levels 
in wild-type Lewis rats (supplemental Table S3). On the other hand, plasma insulin, glucose, and 
triglyceride levels were unchanged in wild-type Lewis rats (supplemental Table S3). 
Effects of central ghrelin treatment on liver lipid metabolism in wild-type Lewis rats 
To assess the central effect of ghrelin on hepatic lipogenesis, mRNA, protein, and activity levels of 
enzymes involved in synthesis and oxidation of lipids were measured in wild-type Lewis rats (Fig. 4, A–
D). Chronic ICV ghrelin infusion significantly increased SCD-1 mRNA levels (Fig. 4A). Protein levels of 
AMPKα1, AMPKα2, pACCα, and ACCα were also significantly increased after the ghrelin treatment 
(Fig. 4, B and C). Similar results were seen in transcript and protein levels of FAS, although it did not 
reach statistical significance. However, the treatment induced an increase in FAS, G6PDH, and 6PGDH 
activities, suggesting an increased lipogenesis de novo (Fig. 4D). On the contrary, CPT1 protein and 
activity levels were reduced by ghrelin infusion (Fig. 4, B–D). In keeping with, the high levels of FAS 
activity, malonyl-CoA was decreased in ghrelin-treated rats (Fig. 4E). 
 
 
 
Fig. 4 Effect of an 8-d ICV ghrelin treatment on hepatic and WAT mRNA (A and 
F), protein (B and C and G and H) and activity levels (D and I) of lipid 
metabolism-related enzymes and malonyl-CoA levels (E and J) in wild-type 
Lewis rats. Values are expressed as mean ± sem. *, **, ***, P < 0.05, 0.01, and 
0.001, respectively, vs. saline. 
  
Effects of central ghrelin treatment on WAT lipid metabolism in wild-type Lewis rats 
To study the effects of chronic ICV ghrelin treatment on WAT lipid metabolism, mRNA, protein, and 
activity levels of the enzymes involved in both synthesis and lipid oxidation were assessed. Ghrelin 
treatment markedly enhanced mRNA levels of the fat storage-promoting enzymes as ACCα, FAS, and 
SCD1 as well as MCD expression (Fig. 4F). These results were confirmed by Western blotting, with ICV 
ghrelin infusion enhancing protein levels of ACCα, pACCα, FAS, and CPT1M (Fig. 4, G and H). The 
activity of those enzymes, as well as G6PDH and 6PGDH, was significantly increased in ghrelin-treated 
rats (Fig. 4I), suggesting a higher lipogenesis rate, which is also supported by increased triglyceride 
content in the WAT of ghrelin-treated animals (vehicle: 110.12 ± 8.52 μmol/g tissue vs. 229.64 ± 15.16 
μmol/g tissue: P < 0.001). In line with the increased FAS and MCD activities in ghrelin-treated rats, 
malonyl-CoA levels were markedly decreased (Fig. 4J), which consequently increased CPT1 activity in 
ghrelin-treated rats (Fig. 4I). 
Effects of central ghrelin treatment on food intake and body weight gain in GH-deficient Lewis rats 
As it happened in normal rats, chronic ICV ghrelin treatment increased food intake (Fig. 5, A and B), 
body weight (Fig. 5C), and food efficiency (Fig. 5D) during the 8-d experimental period in dwarf rats 
when compared with their saline-treated controls. However, ghrelin did not change the total adipose 
tissue mass of dwarf rats (Fig. 5, E and F). 
 
 
 
Fig. 5 Effect of an 8-d ICV ghrelin treatment on cumulative food intake (A), cumulative daily food intake (B), 
body weight gain (C), food efficiency (D), somatic index (E), and sum of retroperitoneal, omental, epididymal, 
and visceral adipose tissue (F) in dwarf rats. Values are expressed as mean ± sem. *, **, ***, P < 0.05, 0.01, and 
0.001, respectively, vs. saline. 
Effects of central ghrelin treatment on plasma parameters in GH-deficient Lewis rats 
ICV ghrelin administration elicited an increase in plasma ghrelin, insulin and glucose levels in GH-
deficient Lewis rats. However, triglyceride levels diminished in these animals after ghrelin treatment 
(supplemental Table S3); these findings agree with other published results (16). 
  
Effects of central ghrelin treatment on liver lipid metabolism in GH-deficient Lewis rats 
To assess the central effect of ghrelin on hepatic lipogenesis in absence of GH, mRNA, protein, and 
activity levels of enzymes involved in synthesis and oxidation of lipids were measured in GH-deficient 
Lewis rats (Fig. 6, A–D). Chronic ICV ghrelin infusion significantly increased mRNA levels for SCD1 
(Fig. 6A). Similarly to normal rats, central ghrelin treatment also induced an increase in the protein levels 
of AMPKα1, pACCα, ACCα, and FAS (Fig. 6, B and C) as well as an increase in the activity of ACC, 
FAS, G6PDH, and 6PGDH (Fig. 6D). Overall, these data suggest that central ghrelin action on hepatic 
lipid metabolism is independent of GH tone. On the other hand, CPT1 protein and activity (Fig. 6, B–D) 
and malonyl-CoA content (Fig. 6E) did not change in dwarf rats after ghrelin administration. 
 
 
 
Fig. 6 Effect of an 8-d ICV ghrelin treatment on hepatic and WAT mRNA (A and F), 
protein (B and C and G and H), and activity levels (D and I) of lipid metabolism-related 
and malonyl-CoA levels (E and J) in dwarf rats. Values are expressed as mean ± sem. *, 
**, ***, P < 0.05, 0.01, and 0.001, respectively, vs. saline. 
  
Effects of central ghrelin treatment on WAT lipid metabolism in GH-deficient Lewis rats 
To study the effects of central ghrelin treatment on adipose lipid metabolism in absence of GH, 
mRNA, protein, and activity levels of the enzymes involved in both synthesis and lipid oxidation were 
assessed in GH-deficient rats (Fig. 6, F–I). Ghrelin treatment enhanced mRNA levels of the fat storage-
promoting enzymes as ACCα, FAS, and SCD1 (Fig. 6F). In GH-deficient rats, ICV ghrelin infusion 
enhanced protein levels of AMPKα1, ACCα, pACCα, and FAS (Fig. 6, G and H). The activity levels of 
these enzymes, G6PDH and 6PGDH as well as CPT1 and MCD, significantly increased in ghrelin-treated 
rats (Fig. 6I); in keeping with these observations, triglyceride levels in the adipose tissue of dwarf rats 
treated with ghrelin have shown a tendency to be up-regulated (vehicle: 300.42 ± 39.71 vs. 401.06 ± 
69.71 μmol/g tissue: P = 0.1). Finally, malonyl-CoA levels did not change after central ghrelin treatment 
in dwarf rats. 
Discussion 
GH plays a major role in the regulation of lipid metabolism, and impairment in the GH axis elicits 
major changes in glucose and lipid metabolism. GH-deficient patients (35) and GH receptor knockout 
mice (GHR-KO) (36–40) display increased insulin sensitivity, insulin secretion, and fasting glucose 
concentrations and increased fat mass. On the contrary, in conditions of GH excess, such as acromegaly 
(41) and after GH administration in GH-deficient adults (42, 43), insulin antagonistic actions of GH are 
well described. The present study shows that in GH-deficient rats, lipogenic enzymes are enhanced 
compared with normal Lewis rats, consistent with the hypothesis that GH decreases adipose tissue 
accretion (44). Our results provide for first time a clear demonstration that chronic central ghrelin 
treatment provokes GH-independent up-regulation of fat storage-promoting enzymes in liver and WAT. 
However, the activity of CPT1, the key enzyme modulating fatty acid oxidation, is enhanced after central 
ghrelin infusion in a GH-independent fashion in WAT. However, activation of the central ghrelin system 
specifically decreases hepatic CPT1 activity in wild-type Lewis rats but not the liver of dwarf rats, 
suggesting GH dependency. Furthermore and contrary to the hypothalamus (17), the present findings 
indicate that in peripheral tissues the increased ghrelin levels during food deprivation do not mediate the 
effects of fasting. In these tissues, starvation downregulates the expression of lipogenic enzymes and 
activates (in liver) or down-regulates (in WAT) CPT1, which are opposite effects to those observed after 
the ghrelin treatment. 
 
Our results show that after 48 h of fasting, the levels of mRNA, protein, and activity of enzymes 
related to lipid synthesis were reduced in both liver and WAT. A reduction in the pentose phosphate 
pathway (based on 6PDGH and G6PDH) was also observed, in accordance with the reduction in the de 
novo lipogenesis (45, 46). To further investigate the role of GH on lipid metabolism, we assayed the 
levels of AMPK. Our data demonstrate that the hepatic levels of pAMPK are decreased after food 
deprivation in wild-type Lewis rats, whereas in GH-deficient rats the levels of both active and total 
protein drop in liver and WAT after 48 h of food deprivation. There are many studies linking food 
deprivation/restriction and AMPK, and the data are controversial. Several reports have shown that AMPK 
is increased by fasting and decreased by refeeding (47, 48). Contrary, Foretz et al. (49) observed that the 
overexpression of a constitutively active form of AMPK in liver markedly attenuates increases in the 
mRNA of lipogenic enzymes, but they did not find a decrease in AMPK activity during refeeding. When 
mice overexpressing GH and mice lacking GH receptor were subjected to long-term caloric restriction, 
protein levels of pAMPK were unaffected (40, 50). Other studies reported a down-regulation of pAMPK 
induced by caloric restriction in rat liver, no change in the fed-fasted cycle in normal and transgenic 
dwarf rats (51) and AMPK activation in rat liver in normal rat fasted by 24 h (52). The exact reasons for 
these discrepancies between the present study and those previous reports are unclear, although we 
hypothesize that the phosphorylation of AMPK may be dependent on time, age, species, and duration of 
the fasting. Further studies are needed to clarify this hypothesis. 
 
Ghrelin is an orexigenic gastrointestinal peptide (19, 53–56) that potently induces GH release (57). 
Ghrelin binds to the GH secretagogue receptor, which is present in not only the hypothalamus and the 
pituitary gland but also many other organs and tissues, indicating that ghrelin may also elicit peripheral, 
GH-independent effects (58). Recent evidence has highlighted that ghrelin acts in the hypothalamus 
modulating lipid metabolism in peripheral tissues, particularly in the WAT (16). There are several studies 
highlighting the importance of GH signaling on the effect of ghrelin on metabolism. Although some data 
from GH-deficient rats have demonstrated that weight gain and adiposity caused by ghrelin are 
independent of its ability to modulate GH secretion (11, 13, 15, 21), ICV ghrelin treatment did not 
increase food intake in GH receptor gene-deficient mice (22), and ghrelin failed to increase the expression 
of GH secretagogue receptor in the hypothalamic arcuate nucleus of dwarf rats (59). Our aim was to 
determine whether ghrelin’s chronic effects on food intake, body weight, and synthesis and oxidation 
pathways of lipids are GH independent. Our data show that central ghrelin treatment enhanced body 
weight, food intake, and food efficiency and increased transcript, protein, and activity levels of enzymes 
related with lipid synthesis in WAT and to a lesser extent in liver. In previous papers it has been reported 
that central ghrelin infusion enhances transcript levels of lipogenic enzymes in adipose tissue and liver, 
but no activity data were shown in those studies (16, 60). Here we demonstrated that in addition to 
mRNA and protein levels, the activity of lipogenic enzymes was increased in both liver and WAT after 
central ghrelin treatment in a GH-independent fashion. Furthermore, the results obtained for activity 
G6PDH and 6PGDH support an increased lipogenesis by ghrelin treatment because they produce 
oxidation of nicotinamide adenine dinucleotide phosphate, which is considered an essential element in de 
novo lipogenesis by supplying reducing power (46). 
 
Central ghrelin effects are particularly intriguing in the case of AMPK, CPT1, and malonyl-CoA 
levels. Preceding studies demonstrated that peripheral and central administration of ghrelin to rats affects 
AMPK activity in a tissue-specific manner. AMPKα is activated in the brain and heart, whereas it is 
inhibited in liver and adipose tissue, and no effect is detected on skeletal muscle (17, 54, 60–63). Our data 
show for first time that chronic ghrelin treatment enhanced protein levels of AMPKα and pAMPKα. ACC 
activity was enhanced after central ghrelin infusion in liver and WAT, but the levels of its product, 
malonyl-CoA, were decreased in both tissues of wild-type Lewis rats. A reasonable explanation for this is 
that central ghrelin treatment increased the activities of FAS (liver and WAT) and MCD (only in WAT), 
leading to an increase of malonyl-CoA turnover. Malonyl-CoA acts as negative mediator of fatty acid 
oxidation by inhibiting CPT-1 and blocking entry of fatty acids into the mitochondria for β-oxidation 
(64). Interestingly, our results suggest that hepatic CPT1 is regulated in a GH-dependent manner because 
we observed that chronic infusion of ghrelin directly into the CNS decreased protein and activity levels of 
CPT1 only in the liver of wild-type Lewis rats and not in dwarf rats. This result suggests that the potential 
of central ghrelin to promote hepatic lipids storage is higher in a GH-dependent- (favoring lipid 
deposition and decreasing lipid mobilization) than in a GH-independent manner (favoring only lipid 
deposition). Contrary to what happens in liver, central ghrelin infusion increased CPT1 protein and 
activity levels in WAT, independent of GH levels. Nevertheless, activation of the central ghrelin system 
may increase lipid oxidation in WAT, and our data indicate that fat mass and fat storage enzymes were 
also stimulated by ghrelin. Thereby, our data suggest that the enhanced β-oxidation in WAT after central 
ghrelin infusion might be a compensatory mechanism and is a GH-independent effect. 
 
Another important observation in the present study is that continuous ICV ghrelin infusion resulted in 
hyperinsulinemia and hyperglycemia only in dwarf rats, although in wild-type Lewis rats, a trend to 
increase was observed for both parameters. The effects of ghrelin on insulin secretion in experimental 
animals are inconsistent. It has been shown to either inhibit or stimulate insulin secretion, depending on 
dose and experimental conditions (65–68). However, systemic action of exogenous ghrelin to elevate 
blood glucose levels has been well documented in humans and rodents (69–71). Several studies have 
demonstrated that the ghrelin system is actively involved in the control of insulin sensitivity and glucose 
metabolism in situations of high-fat diet, GH, and leptin deficiency (72–74). In addition, the ghrelin 
knockout (Ghrl
−/−
) mice on a high-fat diet showed improved levels of insulin, glucose, and lipids 
compared with wild-type mice on this diet and exhibited greater glucose tolerance (75). Our results 
suggest that ghrelin is more important in the control of insulin sensitivity in situations that produce 
metabolic stress, such as the GH deficiency exhibited by spontaneous dwarf rats. Finally, we observed 
that plasma total ghrelin levels were increased in ICV ghrelin-treated rats independently of 
presence/absence of GH. 
 
This increase could be due to an altered ghrelin clearance and/or gastric ghrelin synthesis, a 
phenomenon reported previously by others (16, 73). However, in our opinion, the possibility that increase 
peripheral ghrelin levels contributed to the observed effects was excluded for several reasons. In a recent 
work describing the effects of central ghrelin on adipose lipid metabolism, a pair-fed (animals given the 
same amount of food as consumed by vehicle-treated rats) ghrelin-treated group was included to 
differentiate between ghrelin effects per se from those related to increased food intake. The results 
showed that plasma levels of acyl-ghrelin were increased in the ICV ghrelin-ad libitum group, whereas 
such an increase was absent in the ICV ghrelin pair-fed group. However, despite those differences in 
plasma values, the ghrelin effects on lipid (and glucose) metabolism occurred independently from 
ghrelin-induced hyperphagia, discarding a possible interference of peripheral ghrelin action (16). 
Moreover, in the same study, rats were treated peripherally with the same amount of ghrelin that was 
given ICV to exclude any potential effect of leaking from the cephalospinal fluid (CFS) after central 
ghrelin treatment. Under these conditions, no effects on feeding, body weight, adiposity, or lipid and 
glucose metabolism were detected. Overall, these data exclude and make improbable the existence of 
leaking from the CFS to the blood and instead suggest the existence of a central pathway modulating 
ghrelin action on peripheral lipid metabolism. Moreover, in the plasma it is known that acylated ghrelin is 
quickly deacylated (76). In the CFS this fact is not demonstrated, but to avoid a possible degradation to 
deacylated ghrelin, we infused acyl-ghrelin directly into the brain continuously. Still, the possibility that 
the effects here reported are exerted by des-acyl ghrelin, generated after ghrelin infusion, remains open. 
Further studies assessing the role of nonacylated ghrelin, as well as other peptides generated from the 
ghrelin, are needed. 
 
In summary, our study indicates that: 1) the effects on lipid metabolism in liver and WAT caused by 
starvation are independent of ghrelin, 2) central ghrelin treatment favors lipid storage in a GH-
independent mode in WAT and liver, and 3) ghrelin induces changes in lipid oxidation in a GH-
independent fashion in WAT and in a GH- dependent fashion in liver (decreasing only in normal rats). 
We propose that ghrelin favors energy stores to minimize negative effects in periods of food scarcity. 
During fasting, increased ghrelin levels stimulate appetite and favor the recuperation when the food is 
again available by triggering biological responses that modulate the efficiency of energy storage. 
However, in situations as GH deficiency or diets rich in fat, which contribute a further increase in positive 
energy balance and fat mass (77, 78), the ghrelin’s actions may constitute a harmful mechanism because 
it enhances adipose tissue accretion and/or insulin resistance. Although the role of circulating ghrelin 
levels are not clearly established, (79–81), it has been found that ghrelin levels are decreased in GH-
deficient patients treated with GH (82). The decreased ghrelin levels are correlated with changes in fat 
mass and fat-free mass. The present study suggests that central ghrelin effects can mediate such changes 
in fat metabolism. 
 
Whether a suppression of ghrelin could be useful in controlling adiposity in human obesity associated 
with GH deficiency remains to be established. In any event, understanding the molecular mechanism 
underlying the interplay between GH and ghrelin on lipid metabolism will show new strategies for the 
design and development of suitable drugs for the treatment of GH-deficiency, obesity, and its 
comorbidities. 
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